- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 87,250 | 17.06.24 19:28:41 | +0,550 | +0,63% | 0,000 | 0,000 | 86,300 | 86,700 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 975,800 | 17.06.24 19:14:09 | +23,000 | +2,41% | 0,000 | 0,000 | 967,800 | 952,800 |
